|
|
||||||||
Articles |
Cancer Genetics Unit, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, Australia.
OBJECTIVE: The aim of this study was to determine the primary genetic events that may underlie the formation of parathyroid tumors in patients with lithium-associated hyperparathyroidism (HPT). METHODS: Comparative genomic hybridization (CGH), loss of heterozygosity (LOH) and multiple endocrine neoplasia type 1 gene (MEN1) mutation analysis were used to analyze twelve parathyroid tumors from nine patients with lithium-associated HPT. For comparison, CGH was also carried out in a non-lithium-associated group of thirteen sporadic parathyroid tumors. RESULTS: A higher prevalence of multiglandular disease in the lithium-associated HPT patients compared with the idiopathic sporadic patients was observed (Fisher's exact test, P=0.02). CGH alterations were detected in four lithium-associated parathyroid tumors, involving loss at 1p, 11, 15q, 22q and gain of the X chromosome. In addition, one of these four cases exhibited LOH at 11q13 and was found to contain a novel somatic MEN1 mutation (c.1193insTAC). Although fewer lithium-associated parathyroid tumors were shown to contain genetic alterations compared with the sporadic parathyroid tumors, the changes detected were those frequently associated with both familial and sporadic parathyroid tumorigenesis. CONCLUSION: This is, to our knowledge, the first genetic analysis of parathyroid tumors in lithium-associated HPT patients. Our data indicated that the majority of lithium-associated parathyroid tumors do not contain gross chromosomal alterations and suggest that in most cases the tumorigenic pathway is independent of MEN1 and genes at 1p34.3-pter and 1q21-q32. It is possible that other discrete genetic alterations or epigenetic changes, not screened for in this study, could also be responsible for parathyroid tumorigenesis in lithium-associated HPT.
This article has been cited by other articles:
![]() |
C. Livingstone and H. Rampes Lithium: a review of its metabolic adverse effects J Psychopharmacol, May 1, 2006; 20(3): 347 - 355. [Abstract] [PDF] |
||||
![]() |
V M Howell, C J Haven, K Kahnoski, S K Khoo, D Petillo, J Chen, G J Fleuren, B G Robinson, L W Delbridge, J Philips, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours J. Med. Genet., September 1, 2003; 40(9): 657 - 663. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Marsh, G. Theodosopoulos, K. Martin-Schulte, A.-L. Richardson, J. Philips, H.-D. Roher, L. Delbridge, and B. G. Robinson Genome-Wide Copy Number Imbalances Identified in Familial and Sporadic Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1866 - 1872. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Dwight, A. E. Nelson, G. Theodosopoulos, A. L. Richardson, D. L. Learoyd, J. Philips, L. Delbridge, J. Zedenius, B. T. Teh, C. Larsson, et al. Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism Am. J. Pathol., October 1, 2002; 161(4): 1299 - 1306. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |